Braun Stacey Associates Inc. Takes Position in Gilead Sciences, Inc. $GILD

Key Points

• Braun Stacey Associates acquired 102,562 Gilead Sciences shares worth approximately $12.96 million, while institutional investors and hedge funds collectively own 83.67% of the company.
• Analyst views remain generally positive, with 24 Buy ratings and five Holds producing a consensus “Moderate Buy” rating and an average price target of $158.04, despite several recent target cuts.
• Gilead reported quarterly revenue of $7.8 billion, up 10.6% year over year, and declared a quarterly dividend of $0.82 per share. Insiders sold 105,000 shares worth about $14.24 million over the past 90 days, including sizable sales by two executives under pre-arranged trading plans.

Braun Stacey Associates Inc. acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 102,562 shares of the biopharmaceutical company's stock, valued at approximately $12,958,000.

Several other hedge funds have also added to or reduced their stakes in the business. Persistent Asset Partners Ltd bought a new position in shares of Gilead Sciences during the second quarter valued at $25,000. Strategic Investment Solutions Inc. IL acquired a new stake in Gilead Sciences in the fourth quarter valued at $25,000. Kimelman & Baird LLC acquired a new stake in Gilead Sciences in the second quarter valued at $25,000. Vermillion & White Wealth Management Group LLC raised its position in Gilead Sciences by 71.4% during the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 85 shares during the last quarter. Finally, Quattro Advisors LLC acquired a new position in Gilead Sciences during the 4th quarter worth about $26,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the firm's stock in a transaction on Monday, August 17th. The shares were sold at an average price of $137.64, for a total value of $3,853,920.00. Following the completion of the sale, the insider directly owned 118,234 shares in the company, valued at approximately $16,273,727.76. This trade represents a 19.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Anthony Welters sold 18,000 shares of Gilead Sciences stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $148.62, for a total transaction of $2,675,160.00. Following the completion of the sale, the director directly owned 12,894 shares of the company's stock, valued at approximately $1,916,306.28. This trade represents a 58.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 105,000 shares of company stock worth $14,238,120 over the last ninety days. 0.30% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

GILD has been the subject of several recent research reports. Leerink Partners cut Gilead Sciences from an "outperform" rating to a "market perform" rating and decreased their price target for the company from $146.00 to $127.00 in a research note on Tuesday, July 21st. Maxim Group raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $165.00 price objective on the stock in a research note on Wednesday, May 20th. Weiss Ratings cut Gilead Sciences from a "buy (b-)" rating to a "hold (c-)" rating in a report on Tuesday, August 11th. Barclays decreased their target price on shares of Gilead Sciences from $155.00 to $145.00 and set an "equal weight" rating for the company in a research report on Wednesday, July 29th. Finally, Royal Bank Of Canada boosted their price target on shares of Gilead Sciences from $120.00 to $123.00 and gave the stock a "sector perform" rating in a research report on Wednesday, August 5th. Twenty-four analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $158.04.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: The FDA approved Bixlenvo, a once-daily single-tablet regimen combining bictegravir and lenacapavir for virologically suppressed adults with HIV. It is the first and only single-tablet option for patients on complex regimens who cannot use currently available alternatives, potentially expanding Gilead’s HIV franchise and supporting its longer-term lenacapavir strategy. Reuters FDA approval article
• Positive Sentiment: The European Commission approved Trodelvy plus Keytruda for certain first-line metastatic triple-negative breast cancer patients, strengthening Gilead’s oncology portfolio and adding a potential growth opportunity outside its core HIV business. EU Trodelvy approval article
• Neutral Sentiment: Analysts remain broadly constructive, with a consensus “Moderate Buy” rating and an average price target of approximately $158. However, GILD’s strong multi-year advance may have raised expectations and limited the immediate upside from the Bixlenvo approval. Gilead valuation article
• Negative Sentiment: Director Anthony Welters sold 18,000 shares worth about $2.68 million, reducing his position by roughly 58%. The sale occurred under a pre-arranged Rule 10b5-1 plan, making it a limited bearish signal, but it may still weigh modestly on investor sentiment. SEC insider transaction filing

Gilead Sciences Stock Down 2.1%

Shares of NASDAQ:GILD opened at $145.68 on Friday. The company has a market capitalization of $180.64 billion, a price-to-earnings ratio of -54.56 and a beta of 0.32. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. The business's 50-day moving average is $134.25 and its 200-day moving average is $136.62. Gilead Sciences, Inc. has a 1 year low of $108.46 and a 1 year high of $157.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, topping analysts' consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The business had revenue of $7.80 billion during the quarter, compared to the consensus estimate of $7.40 billion. During the same period in the previous year, the company posted $2.01 earnings per share. The firm's revenue for the quarter was up 10.6% on a year-over-year basis. Equities research analysts predict that Gilead Sciences, Inc. will post -0.5 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be paid a $0.82 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.3%. Gilead Sciences's payout ratio is currently -122.85%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source